Home » Newsletters » BioWorld Science

BioWorld Science

May 31, 1996

View Archived Issues

New bradykinin antagonists from Sanofi Winthrop

Astra reveals analgesic and immunosuppressive agents

Shanghai Institute of Materia Medica reveals epibatidine analogue

Hyal's 3% diclofenac gel: Positive phase III results announced

Efficacy of Peptide Technology's oral psoriasis treatment confirmed

Retinoid antagonists revealed by Eisai

FDA approves piperacillin sodium/tazobactam sodium for new indication

Bayer announces formulation of antibacterial agents

Antiherpes prodrug shows greater activity than aciclovir

Positive results on cidofovir topical gel

Ritonavir granted scientific approval from CPMP

European patent covering lamivudine issued

NSC-645793 and NSC-651016: Anti-HIV agents with potential as clinical candidates

Marketing agreement for trimetrexate glucuronate announced

Unimed announces licensing agreement on its testosterone products

Merck Frosst Canada reveals cyclooxygenase type 2 (COX-2) inhibitors

Di-tert-butylphenol compounds from Proctor & Gamble

Zeneca claims prostaglandin E antagonists

LJP-394 marketing agreement between La Jolla Pharma and Leo Denmark discontinued

Ruthenium complexes revealed by Procept

Meningococcal protein with vaccine potential

Dimethaid Research announces encouraging results with its immunomodulator

LL-95509 exhibits optimum activity against GARFT

M-246315: A new thymidylate synthase inhibitor

Anthracycline antitumor agent FCE-23762 metabolites synthesized

Rebeccamycin analogue undergoes phase I trial

Vinorelbine tartrate and cisplatin cocktail more effective than cisplatin alone

TAS-103, a dual inhibitor of DNA topoisomerase I and II

NSC-314622, a new topoisomerase I-targeted antitumor, described by NIH

Topotecan hydrochloride exhibits positive results in recurrent ovarian cancer patients

RPR-112378: A new inhibitor of tubulin polymerization

Encouraging results reported in paclitaxel and cisplatin-based therapy combination

Daiwa's MGN-3 demonstrates immunotherapeutic activity

Research of a recombinant fusion protein in human breast cancer disclosed

Single-chain immunotoxin targeted to the CD40 antigen effect as cytotoxic agent

Multikine trial commenced

Approval to initiate NOVOMAb-G2 phase I studies granted by the FDA

Encouraging results of IDEC-C2B8 trial reported

IMMU-14 demonstrates evidence of activity

Results of MAb-B1 phase I/II trial announced

MuIGIF with interferon gamma production-stimulating properties identified

Merck & Co. reveals protein farnesyltransferase-inhibiting analogues

More protein farnesyltransferase inhibitors from Warner-Lambert

Cell signaling inhibitor, CTC-119, antitumor activity reported

University of Pittsburgh research reveals GGTI-298, a new geranylgeranyltransferase-1 inhibitor

Ciba-Geigy describes CGP-59326, a powerful antitumor agent

Otsuka reveals matrix metalloproteinase inhibitors

Spicamycin derivative revealed

Dainippon reveals compounds with antitumor activity

NSC-652287D shows important antitumor activity

MF-13 revealed as a selective tumor apoptosis-inducing agent

Ligand reveals RXR-selective retinoid

U.S. Bioscience and Alza embark on marketing agreement for altretamine

C225 shows absence of dose-limiting toxicity

ALRT-1057 exhibits high incidence of complete remission

Sulfone metabolite of sulindac induces apoptosis

A highly lipophilic delta7-PGAI analogue, TEI-9826, demonstrates antitumor activity

ISIS-7597, an antisense oligonucleotide, shows promise in battling multidrug resistance

OC104-26 identified as multidrug resistance (MDR)-reversing agent

Sandoz reports complex for radiotherapy of somatostatin receptor-positive cancers

Carbonic anhydrase inhibitors from Alcon

Ofloxacin ophthalmic solution receives FDA approval

PKC pathway activation may have therapeutic significance in bone disease management

Multicenter clinical trial indicates alendronate effective in osteoporotic fracture prevention

ACAT inhibitors from Warner-Lambert

Celtrix announces the initiation of two phase I trials of SomatoKine

Completion of phase I clinical trials on human red blood cell substitute

Lidocaine transoral patch approved by FDA

Immunoassays for free prostate-specific antigen covered under U.S. patent

Resolution Pharm. enters research agreement

Biomira seeks NDS approval in Canada for Tru-Scint AD

Potential hypoxic marker synthesized by Evanston Hospital

CCD-3693 marketing agreement announced by CoCensys and Searle

Cubist awarded phase II SBIR grants

Creative BioMolecules, Purdue Research Foundation enter collaborative agreement

Promoter region responsible for controlling leptin gene-expression discovered

University of Connecticut awarded U.S. patent on licensed gene delivery technology

Walter Reed Army Institute technology licensed to Jenner Technologies

Chiron and Kosan Biosciences commence collaboration

RPR's riluzole prolongs survival in large international trial

American Home Product reveals M1 receptor agonist

Pentynoic acid derivatives revealed by ABS and the University College Dublin

Gedeon Richter discloses antiamnestic ethers

Neurotrophic polypeptides disclosed by Children's Medical Center

Production of recombinant human basic fibroblast growth factor covered by U.S. patent

Hyaluronic acid and derivatives described by Hyal

FDA approval for RPR's new triamcinolone acetonide formulation

Medeva owns U.S. rights to acrivastine/pseudoephedrine HCI

Nikken Chemicals reports antiallergic/antiinflammatory N-hydroxyureas

Small-molecule alpha4 integrin antagonists generation disclosed by Biogen

Sanofi Winthrop research reveals elastase inhibitors

Endothelin antagonists revealed by Fujisawa

Valsartan approved in Germany

Gene transfer as treatment for myocardial ischemia

Phase II clinical trial on Gensia's second-generation adenosine-regulating agent commence

Taisho researchers reveal cGMP-dependent phosphodiesterase (PDE V) inhibitors

Thrombin inhibitors claimed by Boehringer Mannheim

Yamanouchi reports vasopressin V1 receptor antagonists

Centocor's CenTNF sees positive results

Protein farnesyltransferase inhibitor from Banyu and Merck & Co.

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 15, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 16, 2025.
CTAD 2025: Diagnosing semaglutide’s failure in Alzheimer’s trials
BioWorld
A little over a week after announcing that the Evoke and Evoke+ studies failed to show that oral semaglutide could slow cognition decline in patients with...
Apollo’s APL-4098 shows potent antileukemic effects
BioWorld Science
Apollo Therapeutics Ltd. has developed APL-4098, a small-molecule general control nonderepressible 2 (GCN2) inhibitor for the potential treatment of AML.
ABS-1230 controls seizures in KCNT1-driven severe epilepsy
BioWorld Science
Mutations in the KCNT1 gene produce gain-of-function effects that lead to overactivation of the potassium channel and consequent disruption of normal neuronal...